Prestige Consumer Healthcare (PBH) Income from Continuing Operations (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Income from Continuing Operations came in at 46696000.0 in Q4 2025, down 23.49% year-on-year from 61032000.0 in Q4 2024, and up 10.63% quarter-over-quarter from 42211000.0 in Q3 2025.
Prestige Consumer Healthcare (PBH) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 46696000.0 for Q4 2025.
- On a quarterly basis, Income from Continuing Operations fell 23.49% year-over-year to 46696000.0 in Q4 2025; TTM through Dec 2025 was 186501000.0, a 12.82% decrease from a year earlier, with the FY2025 full-year figure at 214605000.0, up 2.52% from the prior year.
- Income from Continuing Operations grew to 46696000.0 in Q4 2025 per PBH's latest filing, from 42211000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 61032000.0 in Q4 2024 and bottomed at 240552000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 50619000.0 (2021), against an average of 35945300.0.
- Across the five-year window, Income from Continuing Operations plunged 561.84% in 2023 and surged 120.56% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 50215000.0 in 2021, then increased by 3.46% to 51951000.0 in 2022, then grew by 2.11% to 53046000.0 in 2023, then grew by 15.05% to 61032000.0 in 2024, then dropped by 23.49% to 46696000.0 in 2025.
- Per Business Quant, the three latest PBH Income from Continuing Operations figures stand at 46696000.0 (Q4 2025), 42211000.0 (Q3 2025), and 47466000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 46.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.70 Mn |
| Sep 30, 2025 | 42.21 Mn |
| Jun 30, 2025 | 47.47 Mn |
| Mar 31, 2025 | 50.13 Mn |
| Dec 31, 2024 | 61.03 Mn |
| Sep 30, 2024 | 54.38 Mn |
| Jun 30, 2024 | 49.07 Mn |
| Mar 31, 2024 | 49.46 Mn |
| Dec 31, 2023 | 53.05 Mn |
| Sep 30, 2023 | 53.56 Mn |
| Jun 30, 2023 | 53.28 Mn |
| Mar 31, 2023 | -240.55 Mn |
| Dec 31, 2022 | 51.95 Mn |
| Sep 30, 2022 | 51.02 Mn |
| Jun 30, 2022 | 55.27 Mn |
| Mar 31, 2022 | 52.09 Mn |
| Dec 31, 2021 | 50.22 Mn |
| Sep 30, 2021 | 45.33 Mn |
| Jun 30, 2021 | 57.76 Mn |
| Mar 31, 2021 | 35.51 Mn |